A preliminary investigation of the efficacy of an enhanced Cognitive Behavioural Treatment Program for Excessive Worry.
Not Applicable
- Conditions
- Excessive worries in individuals with Generalized Anxiety Disorder (GAD)Mental Health - Anxiety
- Registration Number
- ACTRN12609000807257
- Lead Sponsor
- Hock Lai CHOO, Christopher
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Patients must be 18 years old or older, and must meet the DSM-VI criteria for a primary diagnosis of GAD as assessed on the ADIS-IV.
Exclusion Criteria
Patients who are psychotic, suicidal or have significant substance abuse problems.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean Worry Severity Score as assessed on the Penn State Worry Scale (PSWQ). The PSWQ is a 16-item measure for capturing the excessive and uncontrollable nature of pathological worry, where higher scores indicate more severe worry.[at baseline; at 3, 6, 9 and 12 weeks after treatment commencement; and at 4 and 12 weeks after the completion of the treatment.];Clinician Severity Rating of GAD as assessed on the Anxiety Disorders Interview Schedule - IV (ADIS-IV). The ADIS-IV is a semi-structured interview that assesses for DSM-IV (Diagnostic & Statistical Manual of Mental Disorders, 4th edition) anxiety, mood, somatoform, and substance use disorders, and screens for the presence of other conditions (e.g. psychotic disorders).[at baseline, 12 weeks after treatment commencement, and 12 weeks after completion of treatment.]
- Secondary Outcome Measures
Name Time Method Mean score of the Difficulties in Emotion Regulation Scale. This scale assesses emotion regulation deficits across six dimensions: emotional awareness, emotional clarity, nonacceptance of emotions, difficulty engaging in goal-directed behaviour, poor impulse control, and limited access to emotion regulation strategies.[at baseline; at 3, 6, 9 and 12 weeks after treatment commencement; and at 4 and 12 weeks after the completion of the treatment.]